Power3 Medical announces scientific breakthrough for its NuroPro

May 28, 2009

By Flinn Foundation

[Source: Marketwire] – Power3 Medical Products, Inc. announced today a significant breakthrough related to the diagnosis of patients with Alzheimer’s. This breakthrough, which involved the successful diagnoses of different forms of Alzheimer’s, including high-risk patients, was achieved during the initial phase of clinical validation trials of the Company’s NuroPro® AD blood test. Prospective clinical validation trials of the NuroPro® AD for newly drawn samples, phase one for which is now complete, confirmed previous results recorded by Power3.

The NuroPro AD test was developed to help clinicians diagnose patients with Alzheimer’s, as well as to distinguish those with Alzheimer’s from normal individuals and patients with other neurological disorders. The NuroPro test, developed by Power3, utilizes a panel of blood serum protein biomarkers to determine the probability that a patient has Alzheimer’s. The tests are intended to solve a critical challenge facing physicians, clinicians, and patients toward an objective, early stage and accurate diagnosis of actual disease.

For more information click here.